Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03570619 | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations(IMPACT) | completed | Phase 2 | 56 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT02153151 | Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy | completed | — | 21 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER |
| 1 |
| May 2, 2025 |
| clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT02065726 | Whey Protein Supplementation in Cancer Patients | completed | N/A | 166 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT04328740 | Phase 1 Study of Oral TP-1454 | completed | Phase 1 | 31 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05377528 | Study of AGEN1571 in Participants With Advanced Solid Tumors | completed | Phase 1 | 22 | Agenus Inc.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05878405 | Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer | completed | Phase 3 | 49 | Mayo ClinicOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT04122118 | Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor | completed | N/A | 26 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04694911 | Development of the Oncology Opportunity Cost Assessment Tool | completed | — | 40 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04788758 | Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment | completed | N/A | 76 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05306444 | CLN-418 Study on Subjects With Advanced Solid Tumors | completed | Phase 1 | 48 | Harbour BioMed US, Inc.INDUSTRY | 2 | Apr 25, 2025 | clinicaltrials |
| NCT03260322 | A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | completed | Phase 1 | 169 | Astellas Pharma Global Development, Inc.INDUSTRY | 9 | Apr 24, 2025 | clinicaltrials |
| NCT02717507 | Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors | completed | Phase 2 | 196 | Children's Oncology GroupNETWORK | 4 | Apr 23, 2025 | clinicaltrials |
| NCT03544905 | Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33 | completed | Phase 1 | 206 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT03954067 | A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors | completed | Phase 1 | 72 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04704154 | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | completed | Phase 2 | 175 | BayerINDUSTRY | 8 | Apr 18, 2025 | clinicaltrials |
| NCT04836195 | Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | completed | Phase 1 | 29 | Pacylex PharmaceuticalsINDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT04886622 | A Study of DT2216 in Relapsed/Refractory Malignancies | completed | Phase 1 | 20 | Dialectic Therapeutics, IncINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT00576654 | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 73 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2025 | clinicaltrials |
| NCT04774952 | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors | completed | Phase 1 | 58 | Revolution Medicines, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT04720976 | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 58 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03724890 | Study of Avelumab-M3814 Combinations | completed | Phase 1 | 57 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04943900 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | completed | Phase 1 | 67 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 9, 2025 | clinicaltrials |
| NCT03179436 | Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | completed | Phase 1 / Phase 2 | 415 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT03903705 | : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 348 | HutchmedINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT02454010 | A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer | completed | Phase 1 | 73 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04236414 | Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 6 | Apr 4, 2025 | clinicaltrials |
| NCT04602026 | The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer(RIOT) | completed | N/A | 66 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05963386 | Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors | completed | Phase 2 | 28 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT01877382 | A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 107 | Daiichi SankyoINDUSTRY | 1 | Mar 27, 2025 | clinicaltrials |
| NCT05584111 | Oral Administration of STC-15 in Subjects With Advanced Malignancies | completed | Phase 1 | 42 | STORM Therapeutics LTDINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04716634 | Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors | completed | Phase 2 | 84 | BeiGeneINDUSTRY | 2 | Mar 25, 2025 | clinicaltrials |
| NCT01543763 | Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors | completed | Phase 1 | 90 | Pamela MunsterOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05463432 | A Study of HR19024 in Subjects With Advanced Solid Tumor | completed | Phase 1 | 71 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05225584 | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | completed | Phase 1 | 56 | Kymera Therapeutics, Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02694822 | AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy | completed | Phase 1 / Phase 2 | 89 | Agenus Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 / Phase 2 | 76 | Mereo BioPharmaINDUSTRY | 2 | Mar 17, 2025 | clinicaltrials |
| NCT04907851 | A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)(KEYNOTE-E86) | completed | Phase 2 | 45 | Redx Pharma LtdINDUSTRY | 2 | Mar 17, 2025 | clinicaltrials |
| NCT04172506 | A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 65 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06873542 | A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors | completed | Phase 1 | 10 | Heronova PharmaceuticalsINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04597541 | A Study of AK112 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04882917 | First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) | completed | Phase 1 | 22 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | Mar 7, 2025 | clinicaltrials |
| NCT03444701 | A Study of E7130 in Participants With Solid Tumors | completed | Phase 1 | 62 | Eisai Co., Ltd.INDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | completed | Phase 1 | 162 | MacroGenicsINDUSTRY | 5 | Mar 6, 2025 | clinicaltrials |
| NCT04105335 | A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)(TIMEPOINT) | completed | Phase 1 | 50 | Mina Alpha LimitedINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05134636 | Text-based Intervention to Minimize the Time Burden of Routine Cancer Care(TIME) | completed | N/A | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT01585623 | Drug Interaction Study of SAR302503 in Patients With Solid Tumor | completed | Phase 1 | 16 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04608045 | Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors | completed | Phase 1 | 9 | CicloMed LLCINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 8, 2025source: clinicaltrials